Shockwave™Peripheral Intravascular Lithotripsy Balloon for Advanced Endovascular Aortic Repair

NCT ID: NCT06332911

Last Updated: 2025-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-19

Study Completion Date

2027-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Shockwave TEVAR is a nonrandomized, prospective, international, multi-center, PMCF, obervational study.

The aim of this study is to evaluate the outcomes of the Shockwave™ Peripheral Intravascular Lithotripsy Balloon (Shockwave Medical Inc.) in the routine treatment of hostile iliac accesses during TEVAR and F/BEVAR.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Standardized forms will collect data on the performed procedure, underlying pathology, cardiovascular risks and information on preoperative examinations. Physiological parameters routinely measured prior, during and after any surgical intervention will be recorded as well. A 1 month, 6-months and 12-months follow-up visit will be conducted to assess adverse events and outcome of the index procedure.

In addition, this study aims to analyze the technical and procedure success to gain access via hostile iliac access vessels withShockwave Peripheral Intravascular Lithotripsy Balloon in patients submitted for complex endovascualre thoracic, throaco-abdominal or abdominal aortic repair.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture Abdominal Aortic Aneurysm Without Rupture Thoracic Aortic Aneurysm Without Rupture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

complex endovascular thoracic aortic repair

Patients submitted to complex endovascular thoracic aortic repair with hostile iliac access vessels using the Shockwave device to gain access.

Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+

Intervention Type DEVICE

Cracking-not-debulking technique (SHOCKWAVE IVL)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+

Cracking-not-debulking technique (SHOCKWAVE IVL)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient (m/f) age ≥ 18 years at time of enrollment.
2. Diagnosis of thoracic and/or thoraco-abdominal (Extent I-V) and juxta/para-renal/short-neck aneurysm requiring the implantation of a thoracic and/or thoraco-abdominal fenestrated/branched aortic endograft with delivery system introducer sheath diameter equal or larger than 18 Fr (6 mm).
3. Hostile iliac access was defined in the presence of:

* Heavily circumferential calcified iliac arteries
* Inner diameter ≤ 6 mm
* Severe stenosis (\> 50%; \> 2.5 m/s peak velocity; absence of triphasic duplex signal in ipsilateral common femoral artery)
4. We will accept the following presentations of aneurysm:

* urgent cases,
* elective,
* symptomatic
* and fast growing.
5. The repair was performed using Shockwave™ before the introduction of the main endograft. The iliac procedures can be accompanied by angioplasty and/or stent and stent-graft positioning.

Exclusion Criteria

1. Patients submitted to surgical conduit bypass.
2. Not-severely calcified disease (absence of calcification).
3. In-stent restenosis/occlusion.
4. Inability to cross with 0.014 guidewire.
5. Any significant medical condition which, in the investigator's opinion, may interfere with the subject's optimal participation in the study.
6. Pre-stented iliac access vessels at the level of Shockwave implementation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shockwave Medical, Inc.

INDUSTRY

Sponsor Role collaborator

Rede Optimus Hospitalar SA

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marc Bosiers, Dr.

Role: STUDY_DIRECTOR

Rede Optimus Hospitalar AG

Nikolaos Tsilimparis, Prof.

Role: PRINCIPAL_INVESTIGATOR

Department of Vascular Surgery, LMU Hospital Munich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Vascular Surgery, LMU Hospital Munich

Münich, Bavaria, Germany

Site Status RECRUITING

Department of Vascular Surgery, Klinikum Nürnberg Campus Süd

Nuremberg, Bavaria, Germany

Site Status RECRUITING

University of Genoa School of Medicine, Ospedale Policlinico San Martino - HSM

Genoa, Liguria, Italy

Site Status RECRUITING

Azienda Ospedaliera Universitaria Integrata di Verona

Verona, Veneto, Italy

Site Status RECRUITING

Inselspital, University Hospital Bern, Heart Vascular Center

Bern, Canton Bern, Switzerland

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany Italy Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Phina Muna, Dr.

Role: CONTACT

+49 157 80 58 5869

Annelena Held-Wehmöller, Dr.

Role: CONTACT

+49 157 85128140

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Prof. Nikolaos Tsilimparis

Role: primary

+49 (0)89 4400 73505

Prof. Eric Verhoeven

Role: primary

+49 (0) 911 398-2651

Prof. Giovanni Pratesi

Role: primary

+39 010 555 2424

Prof. Gian Franco Veraldi

Role: primary

+39-045-812-2505

Prof. Dr. Drosos Kotelis

Role: primary

+41(0)031 6325000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RO-231129

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Shockwave IVL + DES
NCT05291247 UNKNOWN
IN.PACT Global Clinical Study
NCT01609296 COMPLETED NA
Stellarex Vascular E-Registry
NCT02769273 COMPLETED